Detalles de la búsqueda
1.
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Breast Cancer Res Treat
; 205(2): 267-279, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38453781
2.
Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.
Future Oncol
; : 1-14, 2024 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38592002
3.
Multicenter Harmonization Study of Pan-Trk Immunohistochemistry for the Detection of NTRK3 Fusions.
Mod Pathol
; 36(8): 100192, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37084942
4.
A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study.
BMC Cancer
; 23(1): 393, 2023 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37131154
5.
MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients.
Genes Chromosomes Cancer
; 61(3): 148-160, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34841595
6.
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study.
Mod Pathol
; 35(10): 1362-1369, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35729220
7.
Circulating proteins as predictive and prognostic biomarkers in breast cancer.
Clin Proteomics
; 19(1): 25, 2022 Jul 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35818030
8.
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
BMC Cancer
; 22(1): 625, 2022 Jun 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35672677
9.
Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox.
Lancet Oncol
; 22(1): e18-e28, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33387500
10.
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Lancet
; 396(10257): 1090-1100, 2020 10 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32966830
11.
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.
J Pathol
; 250(5): 667-684, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32129476
12.
The Functions of the Demethylase JMJD3 in Cancer.
Int J Mol Sci
; 22(2)2021 Jan 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33478063
13.
[How to test for NTRK gene fusions: A practical approach for pathologists]. / Recherche de fusions des gènes NTRK : guide pratique pour les pathologistes.
Ann Pathol
; 41(4): 387-398, 2021 Jul.
Artículo
en Francés
| MEDLINE | ID: mdl-33846022
14.
[2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France]. / Mise à jour 2021 des recommandations du GEFPICS pour l'évaluation du statut HER2 dans les cancers infiltrants du sein en France.
Ann Pathol
; 41(6): 507-520, 2021 Nov.
Artículo
en Francés
| MEDLINE | ID: mdl-34393014
15.
Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance.
Gastric Cancer
; 23(1): 73-81, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31267360
16.
Role of Hormones in Common Benign Uterine Lesions: Endometrial Polyps, Leiomyomas, and Adenomyosis.
Adv Exp Med Biol
; 1242: 37-58, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32406027
17.
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
Semin Cancer Biol
; 52(Pt 2): 16-25, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29024776
18.
Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration.
Histopathology
; 75(2): 225-235, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31017314
19.
[GEFPICS' guidelines for management of breast cancer tissue samples in the neoadjuvant setting]. / Recommandations du GEFPICS pour la prise en charge des prélèvements dans le cadre du traitement néoadjuvant du cancer du sein.
Ann Pathol
; 39(6): 383-398, 2019 Dec.
Artículo
en Francés
| MEDLINE | ID: mdl-31257035
20.
High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast.
Histopathology
; 73(2): 273-283, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29537649